November 01, 2014 7:13 AM ET

Health Care Technology

Company Overview of Caprion Proteomics, Inc.

Company Overview

Caprion Proteomics, Inc. provides proteomics discovery technologies and services to pharmaceutical industries. It offers CellCarta Discovery Platform that enables the discovery of novel targets for therapeutics development and the identification of novel protein biomarkers that reduces risk and enhances clinical development productivity and decision making in pharmaceutical research. The company’s platform is also used to discover novel and insights for targeting and treating cancer and infectious diseases. It offers on-going programs to identify novel tumor cell-surface targets for cancer antibody therapy. Caprion Proteomics, Inc. was formerly known as Caprion Proteomics GP and changed its ...

7150 Alexander-Fleming

Montreal, QC H4S 2C8

Canada

Founded in 2007

Phone:

514-940-3600

Fax:

514-940-3620

Key Executives for Caprion Proteomics, Inc.

Chief Executive Officer
Vice President of Finance
Chief Business Officer and Senior Vice-President
Senior Vice-President of Corporate Development and Diagnostics
Vice President of Biomarker Discovery and Diagnostics
Compensation as of Fiscal Year 2014.

Caprion Proteomics, Inc. Key Developments

Caprion Proteomics Announces Study Results on Development of Blood-Based Diagnostic for Lung Cancer Yields Publication in Science Translational Medicine

Caprion Proteomics announced the results of a major study conducted by Indi (Integrated Diagnostics) which suggests that quantification of a combination of blood proteins can accurately distinguish between benign lung nodules and early-stage lung cancer. The study, which was published in Science Translational Medicine (STM) and includes several Caprion scientists as co-authors, indicates that when the relative concentrations of this group of proteins (or 'classifier') is combined, the classifier result is correct more than 90% of the time in diagnosing benign lung nodules. This multiple protein classifier uses a highly sensitive analytic technique called multiple reaction monitoring mass spectroscopy (MRM-mass spec). The laboratory-based analytical method, combined with sophisticated bioinformatics and systems-biology approaches allowed the researchers to assess the diagnostic power of 371 potential lung cancer biomarkers in millions of different combinations before settling on the diagnostic classifier (set of biomarkers) that these data indicate is most effective.

Similar Private Companies By Industry

Company Name Region
Healthanywhere, Inc. Americas
Heartlink Canada 1999, Inc. Americas
Mobile NewMedia Ltd. Americas
Medipattern Corporation Americas
Prescribed Solutions Consulting Inc. Americas

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Caprion Proteomics, Inc., please visit www.caprion.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.